Clarus Therapeutics
500 Skokie Boulevard
Suite 250
Northbrook
Illinois
United States
Tel: 847-562-4300
Fax: 847-562-4306
Website: http://www.clarustherapeutics.com/
Email: admin@clarustherapeutics.com
50 articles about Clarus Therapeutics
-
The FDA is gearing up for deadlines and PDUFA dates in mid-November with Seagen, Provention, Clarus and Tolmar, and Ligand and Travere.
-
Clarus Therapeutics Holdings, Inc. Announces Plan for Near-Term Sale of JATENZO® Using Structured Process Through Chapter 11 of the U.S. Bankruptcy Code
9/6/2022
Clarus Therapeutics Holdings, Inc. announced that it, together with its wholly-owned subsidiary Clarus Therapeutics, Inc., has filed voluntary petitions under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware.
-
Clarus Therapeutics Reports First Quarter 2022 Financial and Operating Results
5/16/2022
Clarus Therapeutics Holdings, Inc., a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, reported financial results for the first quarter of 2022.
-
Clarus Therapeutics to Report First Quarter 2022 Financial and Operating Results
5/12/2022
Clarus Therapeutics Holdings, Inc. (“Clarus”) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced it will release its first quarter 2022 financial and operating results on Monday, May 16, 2022, after the market closes.
-
Clarus Therapeutics Announces Notice of Allowance for Patent Claims Covering CLAR-121 (Testosterone + Anastrozole) for Treatment of Androgen-Mediated Autoimmune Inflammatory Mastitis
5/10/2022
Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), today announced that it has received a notice of allowance from the United States Patent and Trademark Office (USPTO) for claims that cover certain methods for the treatment of autoimmune inflammatory mastitis that can be achieved by its product candidate, CLAR-121, a proprietary combination of testosterone (T) and anastrozole delivered by a subcutaneous implant.
-
Clarus Therapeutics to Present New Data for JATENZO® (testosterone undecanoate) at the 2022 American Urological Association Annual Meeting
5/9/2022
Clarus Therapeutics Holdings, Inc. (“Clarus”) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced that new data for JATENZO (testosterone undecanoate) will be presented in the form of an abstract at the 2022 American Urological Association Annual Meeting taking place at the New Orleans Ernest N. Morial Convention Center in New Orleans May 13-16, 2022.
-
Clarus Therapeutics Announces Notice of Allowance for Patent Claims Covering JATENZO® (testosterone undecanoate)
4/28/2022
Clarus Therapeutics Holdings, Inc. today announced that it has received a notice of allowance from the United States Patent and Trademark Office (USPTO) for claims that cover its oral testosterone replacement product, JATENZO (testosterone undecanoate).
-
Clarus Therapeutics Announces Closing of Upsized $30.0 Million Underwritten Public Offering
4/27/2022
Clarus Therapeutics Holdings, Inc. announced the closing of its previously announced underwritten public offering of units consisting of 26,680,720 shares of its common stock and accompanying Class A warrants to purchase up to 26,680,720 shares of its common stock and units consisting of pre-funded warrants to purchase up to 590,000 shares of common stock and accompanying Class A warrants to purchase up to 590,000 shares of common stock.
-
Clarus Therapeutics Announces Pricing of Upsized $30.0 Million Underwritten Public Offering
4/25/2022
Clarus Therapeutics Holdings, Inc. today announced the pricing of its underwritten public offering of (i) units consisting of 26,680,720 shares .
-
Clarus Therapeutics Reports Fourth Quarter and Full Year 2021 Financial and Operating Results
3/30/2022
Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today reported financial results for the fourth quarter and full year of 2021.
-
Clarus Therapeutics Announces Closing of Approximately $15 Million Private Placement
12/7/2021
Clarus Therapeutics Holdings, Inc. announced that it has closed its previously announced definitive agreement to sell securities in a private placement with a leading healthcare investor.
-
Clarus Therapeutics Announces $15 Million Private Placement
12/3/2021
Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), today announced that it has entered into a definitive agreement to sell securities in a private placement with a leading healthcare investor.
-
Clarus Therapeutics to Report Third Quarter 2021 Financial and Operating Results
11/17/2021
Clarus Therapeutics Holdings, Inc., a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, announced it will release its third quarter 2021 financial and operating results on Thursday, November 18, 2021, after the market closes.
-
Clarus Therapeutics to Present New Real-World Experience Data for JATENZO® (testosterone undecanoate) at the 22nd Annual Fall Scientific Meeting of SMSNA
10/14/2021
Clarus Therapeutics Holdings, Inc. announced that new real-world experience data for JATENZO® will be presented at the 22nd Annual Fall Scientific Meeting of the Sexual Medicine Society of North America, taking place at The Westin Kierland in Scottsdale, Arizona, October 21-24, 2021.
-
Clarus Therapeutics and McGill University Announce Exclusive Worldwide Licensing Agreement To Develop and Commercialize Technology To Treat Rare Conditions Associated With Coenzyme-Q10 (Ubiquinone) Deficiencies
9/16/2021
Agreement to accelerate development of potential treatments for rare, endocrine, metabolic, and neurological conditions associated with primary and secondary ubiquinone deficiencies which belong to the wider class of mitochondrial diseases
-
Clarus Therapeutics Closes Transaction With Blue Water, Debuts as a Publicly Traded Company to Develop Androgen and Metabolic Therapies
9/9/2021
Blue Water Acquisition Corp., a special purpose acquisition company, completed on September 9, 2021 Combined company to be renamed Clarus Therapeutics Holdings, Inc.
-
Clarus Therapeutics Announces Comprehensive Settlement of Patent Litigation With Lipocine
7/15/2021
Clarus and Lipocine (NASDAQ: LPCN) agreed to settle all outstanding claims in the patent infringement lawsuit brought against Clarus by Lipocine and to further resolve a patent interference between the parties.
-
Clarus Therapeutics And HavaH Therapeutics Announce Licensing Agreement For Product To Treat Androgen-Dependent Inflammatory Breast Disease And Certain Forms Of Breast Cancer
5/25/2021
Agreement aims to accelerate development of a unique testosterone treatment for inflammatory breast diseases and estrogen-receptor positive breast cancer
-
Blue Water Acquisition Corporation Announces Merger Agreement with Clarus Therapeutics, Forming A Publicly Listed Company To Address Unmet Needs Of Men And Women Through Development Of Androgen And Metabolic Therapies
4/27/2021
Existing Clarus investors, led by H. I. G. Capital, will invest an additional $25 million in support of the company Transaction will accelerate commercialization of JATENZO®, the market-leading oral testosterone replacement therapy, and fund expansion of the company's pipeline of androgen and metabolic therapies for men and women, including orphan indications Clarus Therapeutics shareholders and Blue Water Acquisition Corp. shareholders will hold shares in Clarus Therapeutics
-
Clarus Therapeutics Presents Positive Safety And Efficacy Data For JATENZO® (Testosterone Undecanoate) Oral Capsules, CIII At ENDO 2021, The Endocrine Society's Annual Meeting
3/20/2021
Data from a two-year study supports JATENZO as an effective long-term oral testosterone replacement therapy for hypogonadal men, maintaining normal testosterone levels with no evidence of liver toxicity